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Multiple studies in the recent years suggest that the microbiome is
critically important for normal host functions, while impaired host
microbiome interactions contribute to the pathogenesis of
numerous common disorders. Of these, much attention is recently
given to the involvement of the microbiome in the pathogenesis of
impaired glucose tolerance, type II diabetes mellitus (T2DM), and
other metabolic disorders comprising the 'metabolic syndrome',
including obesity, non-alcoholic fatty liver disease and their
complications. In addition, alterations in the microbiome have
been linked to the pathogenesis of type 1 diabetes mellitus
(T1DM), an autoimmune disorder affecting the glycemic response,
of distinct pathogenesis than T2DM. In this chapter we will discuss
the roles of the microbiome in regulating the normal and impaired
glycemic response in both mice and humans, and outline examples
of underlying mechanisms by which the microbiome is contrib-
uting to diabetes mellitus. We will further discuss means by which
the microbiome can be manipulated to develop future therapeutic
interventions for hyperglycemia and its adverse effects.
© 2016 The Authors. Published by Elsevier Ltd on behalf of
European Society for Clinical Nutrition and Metabolism. This is an
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The term ‘diabetes mellitus’ denotes two distinct metabolic disorders that share the common
feature of chronic hyperglycemia and impaired glycemic response due to defects in insulin secretion,
sensitivity or both. Type 1 diabetes mellitus (T1DM), is an autoimmune condition involving the
destruction of beta cells in the pancreas, consequently leading to impaired production of insulin,
rendering patients entirely dependent on exogenous insulin. T1DM accounts for ~5e10% of diabetes
mellitus cases, and is characterized by abrupt onset in children and young adults. In contrast, type 2
diabetes mellitus (T2DM, previously termed non-insulin dependent diabetes mellitus) is characterized
by impaired insulin sensitivity of target tissues (muscle, liver, adipose tissue), leading to impaired
glucose uptake into peripheral tissues, a condition termed ‘insulin resistance’. During most of the
course of T2DM, insulin secretion is increased due to pancreatic beta cell compensation for insulin
resistance, and only at late stages of T2DM pancreatic insulin secretion is impaired, leading to exog-
enous insulin dependency. Due to the gradual nature of this process, T2DM is mostly but not exclu-
sively observed in adults [1]. Despite the differences in epidemiology and pathogenesis, the
microbiome is suggested to play a role in the manifestation or progression of both T1DM and T2DM as
outlined below.
T1DM. In addition to the existing mechanistic knowledge regarding the pathogenesis of T1DM, gut
microbiome alterations also seem to be a feature of this autoimmune disorder. The classical murine
model for T1DM is the non-obese diabetic (NOD) polygenic mutant mouse, in which animals develop
spontaneous insulitis and consequently depletion of insulin production at about 12 weeks of age.
When these mice additionally lack MyD88 (an adaptor for multiple receptors that recognize microbial
patterns), they are protected from the development of T1DM, suggesting that microbial stimuli may be
involved in disease pathogenesis in this model. Interestingly, deriving these mice as germ-free (GF) or
treating them with broad-spectrum antibiotics leads to robust development of T1DM. Moreover,
recolonizing NOD GFmicewith a deﬁnedmicrobiota reduced the incidence of diabetes, suggesting that
certain microbiome compositions may play a protective role in the development of T1DM [2]. This
observation and follow up studies have led to the development of the ‘balanced signal’ hypothesis, in
which various members of the microbiome may promote T1DM while others have an inhibitory
function [3e5]. T1DM-promoting microbial composition may be induced by early exposure to anti-
biotics [6] (as discussed in the next section). The downstreammicrobiome effects on host susceptibility
to T1DM may involve microbial-mediated alterations in host sex hormones [7,8], induction of host
immune reactivity, mainly the Th17 response [9,10], as well as other, yet unidentiﬁed factors.
Support for the conclusions obtained in the above murine models can be found in human trials. In a
small-scale prospective caseecontrol study performed in eight children, a signiﬁcant microbial dys-
biosis was apparent early after the onset of autoimmunity, with increase of Bacteroidetes (and more
speciﬁcally, the genus Bacteroides) and consequent reduction of Firmicutes noted in new onset T1DM
cases [11]. Other studies suggested that butyrate producing bacteria may be also reduced in T1D pa-
tients [12], possibly leading to alteredmucin synthesis and compromised intestinal integrity, leading to
systemic inﬂux of microbial antigens inducing autoimmunity. Similar taxonomic differences were
reported in a different cohort of children [13]. A recent longitudinal study with 33 infants determined
that microbiomes of subjects who progress to T1D are characterized by signiﬁcant reduction in alpha
diversity even before the onset of clinical symptoms. In the children who progress into T1DM, several
correlations were determined between distinct microbial taxa and serum or fecal metabolites that
were previously associated with diabetes, suggesting that these microbe-metabolite relationships may
cooperatively impact T1DM pathogenesis [14]. Despite this increasing number of reports, our
knowledge regarding the role of the microbiome in T1D remains mostly descriptive. Further research is
needed to fully understand the contribution and the function of themicrobiome in themanifestation of
T1DM.
T2DM. Multiple studies suggested an association between compositional and functional micro-
biome alteration (‘dysbiosis’) and the risk of developing metabolic syndrome-associated pathologies
such as obesity, T2DM, non-alcoholic fatty liver disease and hyperlipidemia. In mice, induction of in-
sulin resistance may be induced by alteration of the microbiome, mediated by changes in diet and
immune dysregulation, as further discussed in the next section.
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alterations. In a study of 292 Danish individuals, Le Chatelier et al. reported that participants with
insulin resistance (as well as increased adiposity) are characterized by lower bacterial richness [15] and
have higher abundances of Proteobacteria and Bacteroidetes. Larsen et al. also reported higher
abundances of the same phyla in diabetic males as well as a positive correlation between Bacter-
oidetes-to-Firmicutes ratio and elevated plasma glucose levels. In contrast, no differencewas detected
in bacterial alpha diversity [16]. In their cohort of 345 Chinese individuals, Qin et al. also reported
association between T2DM and higher levels of E. coli and Bacteroides, as well as Akkermansia
muciniphila and various Clostridia [17]. Functional analysis revealed that the microbiome of these
diabetic individuals was enriched for pathways or modules involved in membrane transport, methane
metabolism, xenobiotics degradation and metabolism, and sulphate reduction, while pathways of
bacterial chemotaxis, ﬂagellar assembly, butyrate biosynthesis and metabolism of cofactors and vita-
mins were decreased. Consistent with Qin et al., Karlsson et al. performed a functional analysis of
microbiome from T2DM females and controls [18] and reported that the diabetic group featured
enrichment of genes related to membrane transport and oxidative stress. Among the additional
commonalities were the enrichment of ﬂagellar assembly and riboﬂavin metabolism pathways in the
non-diabetic controls, and high levels of various Clostridia in the diabetic group. Interestingly, analysis
of themetagenomic data from the Chinese cohort suggested that not only themicrobiome composition
and function associate with T2DM, but also the growth dynamics of the microbiome, as for several
commensal bacteria, including E. coli, Bacteroides or Butyrate-producing bacterium SS3/4, growth
rate was correlated with elevated blood glucose, glycosylated hemoglobin A1c (HbA1c) and T2DM [19].
T2DM treatment may also affect the microbiome. A recent study by Forslund et al. [20] investigated
the human gut microbiome of T2DM patients obtained from three different human gut microbiome
cohorts including the Chinese [17] and the Danish [15] studies mentioned above and another new
T2DM and non-diabetic cohort. In all three cohorts, patients clustered by metformin treatment, with
metformin causing a shift in the gut microbiome and increasing the microbiome richness. More spe-
ciﬁcally, metformin treatment increased Escherichia and lowered Intestinibacter species abundance
and led to induction of short chain fatty acids production. Therefore the impact of anti-diabetic
medication on the gut microbiome needs to be considered in developing microbiota-based diag-
nosis and therapy for T2DM. In all, T2DM and its treatment are suggested to have major effects on the
gut microbiome, yet despite these associations and several commonalities in microbial composition
and function, no distinct microbial “signature” was fully shared between all T2DM patients in these
different studies.
2. Factors contributing to microbial alterations in T1D and T2DM
Themicrobiome composition of healthy adult humans is considered to be generally stable over time
[21]. Nevertheless, several factors have been suggested to alter and predispose the healthy microbiome
to a conﬁguration that contributes to an impaired glycemic response (Table 1). Better understanding of
these factors and the mechanisms that shift the microbiome towards a harmful conﬁguration may
produce better prevention and intervention strategies.
Antibiotics. The use of antibiotics was a critical turn in modern medicine and saved countless lives
by treating and preventing pathogenic infection, yet their effects on the gut microbiota may sometimes
result in harmful health consequences. In T1DM-susceptible NODmice, treatment with vancomycin or
neomycin or, in a separate study, a broad spectrum combination of streptomycin, colistin and ampi-
cillin starting in early life accelerates the onset of T1DM in adulthood [6,22]. Similar ﬁndings were
reported in NOD-MyD88 knockout mice, in which treatment with sulfatrim throughout the lifetime of
themouse promotes higher rates of T1DM [2]. Recently, this notion has been expanded to development
of diabetes mellitus in humans. In a case-control study of over 1 million participants, Boursi et al. [23]
observed that repeated treatment with antibiotics (between two and ﬁve rounds) early in life increases
the risk of developing both T1DM and T2DM, in a dose-dependent manner. Similar ﬁndings were
reported for T2DM in a case-control study performed in the Danish population byMikkelsen et al. [24].
It is important to note that reverse causality is a potential limit of these studies. Both T1DM and T2DM
patients are known to be at higher risk for various infections [25], leading to heavier antibiotic usage
Table 1
Factors that alter the microbiome and consequently affect glycemic control.
Factor Effect on the microbiota Effect on the host
High-fat diet (HFD) Increase: Proteobacteria, Firmicutes/
Tenericutes/Mollicutes
Decrease: Bacteroidetes, alpha diversity
Endotoxemia, obesity, insulin resistance
Low-calorie diet Increase: Bacteroidetes
Decrease: Firmicutes
Weight loss
Non-caloric sweeteners:
Saccharin
Increase: Bacteroides (mice)
Decrease: Clostridiales (mice)
In humans: Disbiosys in some
Glucose intolerance
Non-caloric sweeteners:
Aspartame
Increase: Clostridium leptum
Decrease: Clostridium cluster XI
(on HFD)
Elevated fasting glucose, impaired insulin tolerance
Dietary emulsiﬁers Increase: Mucolytic OTUs (e.g.
Ruminococcus gnavus)
Decrease: Bacteroidales
Weight gain, adiposity, impaired glycemic control,
colitis
Pregnancy Increase: Proteobacteria, Actinobacteria
Decrease: Butyrate-producers, alpha
diversity
Glucose intolerance, increased adiposity and levels of
inﬂammatory markers
Bariatric surgery Increase: Proteobacteria/E. coli,
Clostridiales
Decrease: Firmicutes
Weight loss, reduced adiposity, improved insulin
tolerance
Jet lag Dysbiosys (mice and humans) Weight gain, glucose intolerance
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diabetes in these patients. One suggested mechanism for a causative antibiotic-diabetes link is
antibiotic-mediated changes in microbiomemetabolism, leading to reduction of short chain fatty acids
(SCFA), which may promote T1DM by increasing gut permeability [12]. Given these interesting yet
inconclusive correlations, the association between antibiotic use and the risk of either T2DM or T1DM
merits further prospective validation.
Diet. The type and amount of consumed foods play an important role in both establishing the
metabolic syndrome, and in shaping the gut microbiome [26e28]. It is therefore surprising that
causative association between different types of diets, the gut microbiome, and health consequences
is currently sparse. The most well studied diet in the context of microbiome and risk for metabolic
syndrome is a diet rich in fat; this diet alters the gut microbiome and promotes metabolic syndrome
when microbiome from obese mice is transplanted to GF recipients [29e32]. Weight reduction diets
alter the composition of the microbiome (i.e. less Firmicutes, more Bacteroidetes), yet this may be a
result of the changes in weight rather than a direct effect of the diet on the microbiome [33].
Interestingly, the effect of the microbiome on host metabolism is dependent not only on the amount
of fat but also on its source; compared to mice fed a diet containing ﬁsh oil, mice fed a diet with lard
exhibited exaggerated weight gain, white adipose tissue inﬂammation and impaired insulin sensi-
tivity. These detrimental effects of the lard were due to its association with a distinct microbial
composition, which led to induction of adipose tissue inﬂammation [32]. It remains to be determined
how other diets affect the microbiome, and how the microbiome-diet interactions govern metabolic
homeostasis.
Food additives. Modern human diet has been dramatically altered in the last decades, including the
addition of multiple synthetic ingredients into human nutritional repertoire. One such example is non-
caloric artiﬁcial sweeteners, which are consumed bymillions worldwide tomaintain the sweet taste of
foods without the associated calories. While replacing caloric with non-caloric sweeteners is widely
endorsed [34], studies in both humans and rodents associate their consumption with the counter-
intuitive effect of promoting insulin resistance and weight gain (reviewed in [35]). We have recently
demonstrated that mice consuming saccharin, sucralose or aspartame develop glucose intolerance,
which was ameliorated by antibiotics treatment. Saccharin signiﬁcantly altered the composition and
function of the microbiome, with concomitant increase in Bacteroides and pathways involved in the
degradation of glycans [36]. Importantly, the dysbiotic microbiome had a causative role in the
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to our results, Palmn€as et al. also reported impaired insulin-stimulated glucose disposal following
aspartame consumption, as well as microbial dysbiosys [37]. In humans, we have reported in a small-
scale preliminary experiment that some individuals show microbiota-dependent development of
glucose intolerance following acute consumption of saccharin. The full scope of this susceptibility in
the population and the effect of chronic long-term consumption of various non-caloric sweeteners
merits further research.
Another example of recently introduced food ingredients whose effects on the microbiome may
contribute to metabolic consequences in the host, are dietary emulsiﬁers, heavily used by the modern
food industry. Chassaing et al. [38] showed that two commonly used dietary emulsiﬁers derived from
processed food alter the composition of the gut microbiome and predispose to increased intestinal
permeability and elevated circulating LPS levels. Emulsiﬁer supplementation to mice led to enhanced
adiposity and food intake and elevated blood glucose levels. Importantly, these metabolic phenotypes
were abrogated in GF mice, while transfer of microbiota from conventional mice treated with emul-
siﬁers into GF recipients resulted in development of the metabolic disorders. This study suggests that
dietary emulsiﬁers may cause a combination of microbial dysbiosis and impaired host intestinal barrier
function, promoting obesity-induced metabolic manifestations.
Pregnancy. Several metabolic changes that occur throughout pregnancy are also characteristic of
metabolic syndrome, including insulin insensitivity. Koren et al. [39] characterized pregnant women
and determined that the fecal microbiome of the third trimester is signiﬁcantly altered, with increase
of Proteobacteria and Actinobacteria and reduction in some butyrate-producers and alpha diversity.
To determine whether these alterations may contribute to the metabolic parameters, fecal microbiota
from the third trimester were transplanted into GF mice. Recipient GF mice showed glucose intoler-
ance, as well as increased adiposity and inﬂammatory markers. In contrast to the above study, a recent
study by DiGiulio et al. [40] examined themicrobiota composition in the vagina, stool, saliva andmouth
of pregnant womenwho undergo full term deliveries compared to preterm cases. The study suggested
that during pregnancy the microbiota composition remains stable in all the sites. In women who
subsequently delivered prematurely the vaginal community was modiﬁed characterized by increased
Peptoniphilus, Prevotella, and Anaerococcus while decreased Lactobacillus species. Further studies
may investigated possible population and obstetric differences that may resolve these different
pregnancy-related results. It will be interesting to determine whether microbiome alterations are
associated with some pregnancies, and whether they persist after pregnancy and contribute to the
development of the metabolic syndrome later in life.
Immune response. Innate immune signaling may directly cause dysbiosis and induce metabolic
disorders in response to obesity [41]. Toll-like receptors (TLRs) are one of the central innate immune
sensors, activating a pro-inﬂammatory pathways involving Myd88 and NF-kB, leading to transcription
of inﬂammatory cytokines and other factors [42]. However, conﬂicting results were reported about the
effect of TLR signaling on glucose and weight control. Obese and insulin resistant mice [32] as well as
T2DM patients [41] showed increased TLR2 and TLR4 expression, which was associated with the
severity of insulin resistance. Accordingly mice with mutated CD14, which is the TLR4 co-receptor [43],
and mice with ablation of TLR4 in hematopoietic cells [44] featured decreased obesity-induced glucose
tolerance and insulin resistance. However, mice lacking Myd88 [45] and TLR5 [46] showed increased
body weight and glucose intolerance. Deleterious TLR5 signaling caused dysbiosis and the metabolic
effect was transferable to GF mice, while antibiotics abrogated the metabolic perturbations, suggesting
that the microbiome plays a central role in the pathogenesis that governs the progression of the
metabolic syndrome abnormalities [46].
A recently identiﬁed family of cytoplasmic innate sensors is the nucleotide-binding-and-
oligomerization domain and leucine-rich-repeatecontaining (Nod-like receptor, NLR) family. Path-
ogen- and damage-associated molecular patterns are able to induce a cytoplasmic multi complex
termed inﬂammasome composed of speciﬁc NLR, which may include the adaptor protein ASC
(PYCARD), promoting proximity cleavage of Caspase-1 and catalytic activation of IL-1b and IL-18, as
well as a cell death termed pyroptosis. Expression of Nod-like receptor-3 (NLRP3) inﬂammasome is
enhanced in adipose tissues and livers of obese mice and humans and correlates with the severity of
T2DM, whereas reduced adipose NLRP3 inﬂammasome is associated with improved insulin sensitivity
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tolerance but ablation of other inﬂammasome components such as Caspase1 led to improved glucose
homeostasis [49]. Mice with defective NLRP3, NLRP6 and ASC inﬂammasome exhibited dysbiosis and
developed nonalcoholic fatty liver disease (NAFLD) [48]. Importantly, the metabolic phenotype was
directly caused by modiﬁed gut microbiota conﬁguration associated with exacerbated fatty liver via
inﬂux of TLR4 and TLR9 ligands into the portal circulation, leading to hepatic inﬂammation and
development of steatosis [48]. Similarly, ASC-deﬁcient mice develop increased obesity and loss of
glycemic control on high-fat diet feeding and the metabolic effect was mediated by the gut microbiota
since it was transferable to wild-type mice and abrogated by antibiotics [48].
All together, TLR and NLR innate sensors modulates gut microbiota composition and function,
which in turn may control whole body glycemic response in steady state and in obesity and its asso-
ciated metabolic disorders.
Alterations in gut permeability. A change in gut permeability and immune cells composition was
recently noticed in response to obesity. In obese mice modiﬁed gut permeability [50] and a shift in
intestinal pro-inﬂammatory adaptive immune cells [51] led to changes in the gut microbial compo-
sition and function and contributed to insulin resistance and glucose response through changes in
intestinal barrier function, endotoxemia and adipose tissue inﬂammation. Treatment of obese mice
with the gut-speciﬁc anti-inﬂammatory agent mesalamine (5-ASA), which is used as therapy for in-
ﬂammatory bowel disease (IBD), reversed the activation of gut adaptive immune cells, microbial
dysbiosis, adipose inﬂammation, rescued systemic endotoxemia and improved insulin sensitivity [51].
Bariatric surgery. Bariatric surgical procedures are currently considered an effective treatment for
sustained weight loss and reduction of obesity-related comorbidities, including T2DM [52]. Several
studies have reported that in addition to improvement of clinical and metabolic markers, Roux-en-Y
gastric bypass (RYGB) operations also alter the composition of the gut microbiome in correlation
with the improved metabolic parameters. A common trend is observed in these studies, namely the
post-operation reduction in relative abundance of Firmicutes and increase in the abundance of Pro-
teobacteria (or more speciﬁcally, E. coli) [53e56]. Nevertheless, the majority of studies characterizes
the short-term effects of the surgery on themicrobiome, and do not demonstrate a causal link between
microbial alterations and improvement in metabolic markers. In a recent study, Tremaroli et al., fol-
lowed operated-women 9 years post-operation (RYGB or vertical banded gastroplasty) with compar-
ison to obese or BMI-matched controls, and reported that some of the microbial alterations persist for
long-term, including the increase in Escherichia and some Clostridia [57]. Transplantation of micro-
biota from post-operation patients and control obese subjects to GF mice demonstrated reduced
adiposity and improved metabolism (measured as respiratory exchange rate) in recipients receiving
the post-operated microbiota. These ﬁndings suggest that controlling the microbiome composition
after bariatric surgery may aid in the maintenance of the improved clinical and metabolic parameters.
Disturbances to circadian behavior. Chronic jet lag and shift work are behavioral patterns that
involve the disruption of normal circadian rhythmicity, and are associatedwith increased risk for obesity,
diabetes, and cardiovascular disease. We and others have recently reported that the gut microbiome
composition and function oscillate in a rhythmic fashion due to dietary and host cues in both mice and
humans [58e61]. These oscillations are abrogated inmice that experience circadian rhythm impairment,
consequently leading to obesity and glucose intolerance. In humans, similar sleep-wake alterations
(induced by severe jet lag) alter the composition of the microbiome, and when the microbiota was
transplanted to GFmice they developed glucose intolerance and gainedmoreweight [58]. Feedingmice a
high-fat diet also perturbs microbiome circadian oscillations, while forced night time feeding has a
protective effect in preserving a normal microbiome composition and preventing diet-induced obesity
and glucose intolerance [59,60]. Together, these studies suggest that timing of feeding, in addition to the
feeding content, has signiﬁcant effects on themicrobiome, while changes in circadian behavior may alter
the microbiome in ways which may promote risk for glucose intolerance and T2DM.
3. Mechanisms of microbiome-mediated regulation of the glycemic response
Microbiota-related metabolites play pivotal role in regulation of host glucose homeostasis. Micro-
biota composition and function can integrate the functional states of food intake, affecting whole body
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obesity and T2DM [62]. Microbiota modiﬁcation and production of diet metabolites and inﬂammatory
factors plays a central role in controlling whole body glucose homeostasis. The most well studied
microbiota-derived metabolites affecting the glycemic response are short chain fatty acids and bile
acids. In this section, we will discuss how these metabolites regulate the glucose response of the gut,
liver, pancreas and adipose tissues, inﬂuencing systemic glycemic response in steady state and in
obesity-induced T2DM (Fig. 1). We will further highlight inﬂammatory factors produced or induced by
the microbiota that affect the host immune response, thereby contributing to insulin resistance and
impaired glycemic response.
Short chain fatty acids. Short chain fatty acids (SCFA) including acetate, propionate, and butyrate
are widely studied metabolites that are produced by bacterial fermentation of polysaccharides. Diet
supplementation with SCFA leads to improved glucose tolerance and insulin sensitivity in both lean
and obese and diabetic humans and rodents [63,64]. The SCFA butyrate and propionate bind the G-
protein coupled receptors GPR41 (FFAR3), GPR43 (FFAR2), and GPR109A mainly expressed in colonic
epithelium, adipose tissue and pancreatic beta cells. The cells in the colonic epithelium utilize the SCFA
produced by the bacteria as an energy source, while GF mice have low SCFAs and are energy deprived
with deﬁcit in mitochondrial oxidative phosphorylation and ATP levels leading to autophagy [65]. SCFA
act through GPR41 and GPR43 to induce secretion of the incretin glucagon like peptide-1 (GLP1) from L
cells and thus can contribute to glucose control [66] and gastric emptying [67]. The effect can be
mediated by coupling of the receptors to Gaq protein, resulting in increased intracellular calcium levels
[66].
GPR43-deﬁcient mice gained more weight on a normal diet with increased adiposity, weight,
glucose intolerance and insulin resistance in response to obesity, and mice with GPR43 overexpression
in adipose tissues exhibited no change in weight gain in response to high-fat diet feeding [68].
Importantly, GF mice that were deﬁcient of GPR43 displayed a normal weight and glycemic phenotype,
suggesting that bacterial SCFA induce GPR43 activation leading to reduced insulin-mediated fat
accumulation, promoting lipids and glucose homeostasis [68]. GPR43 is a potent inhibitor of inﬂam-
matory response [69] expressed in immune cells. Since the inﬂammatory response has a substantial
role in driving obesity-associated pathologies including T2DM [70], it is possible that regulation of
immune function via GPR43 may contribute to improved glucose control and insulin sensitivity
mediated by SCFAs. Mice lacking GPR41 were leaner compared to control mice and showed reduced
expression of the enteroendocrine hormone PYY that normally inhibits gut motility, with reduced
energy harvest from the diet. No difference in weight was observed in GF GPP41 null mice, suggesting
that the effects of GPR41 on weight and energy balance is mediated by the microbiota.
De Vadder et al [64] showed that butyrate and propionate could also promote intestinal gluco-
neogenesis by two different mechanisms to advance energy metabolism. Butyrate induces transcrip-
tion of intestinal gluconeogenic genes in enterocytes via cAMP. Propionate acts on GPR41 to induce a
gut-brain neural circuit leading to conversion of propionate to glucose, resulting in modiﬁed gut
microbiota composition, reduced adiposity and improved glucose control [64].
Another receptor for b-D-hydroxybutyrate (themajor ketone body in circulation) is GPR109A, which
is a niacin receptor. GPR109A induce anti lipolytic effect decreasing free fatty acids levels, whereas the
role of butyrate-GPR109A in glucose regulation has not been elucidated to date [71]. Butyrate is a well
known histone deacetylase (HDAC) inhibitor [72], yet the connection to its beneﬁcial effect on energy
metabolism remains unknown. Although the presented data propose a pivotal function of SCFAs and
their cognate receptors in metabolism, SCFAs can enter the cell by diffusion or transporters, suggesting
the metabolic effects mediated by SCFA can occur via mechanisms independent of their receptors.
Bile acids. Bile acids are derived from hepatic cholesterol catabolism. Newly synthesized bile acids
are conjugated and transported into the gallbladder and postprandial contraction of the gallbladder
empties the bile acids into the intestinal lumen [73e75]. In addition to their role in dietary fat
digestion, bile acids are now recognized as important regulators of lipid metabolism, energy homeo-
stasis and glycemic control.
Bile acids strongly interact with the gut microbiota. In the intestine microbial enzymes can modify
the primary bile acids into secondary bile acids, facilitating the digestion and absorption of dietary fats.
The central role of gut microbiota in regulating bile acid conjugation is demonstrated in mice treated
Fig. 1. Microbiota effects on the glycemic response.
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J. Suez et al. / Clinical Nutrition Experimental 6 (2016) 59e73 67with antibiotics or GF mice, which showed reduced secondary bile acids and decreased bile acid di-
versity [76e79]. Sayin et al. [78] showed that the gut microbiota mediate their effect on bile acids
mainly via regulating the nuclear receptor farnesoid X receptor (FXR, also known as NR1H4) and its
target gene ﬁbroblast grown factor 15 (Fgf15) [78]. In the liver Fgf15 act together with hepatic Fgf4 to
inhibit the expression of cholesterol 7-a-hydroxylase (Cyp7a1), which is a rate-limiting enzyme in bile
acid biosynthesis. Obese and insulin resistant mice show decreased gut microbiota diversity accom-
panied with reduction in bile acids composition and abundance, increased FXR and Fgf15 expression in
the ileum and decreased hepatic Cyp7a1 [80]. The role of FXR in obesity development was demon-
strated in mice lacking both leptin and FXR [81] and mice with over-expression of hepatic Cyp7a1 [82]
that exhibited protection from development of obesity and insulin resistance. Ryan et al. [83] showed
that the beneﬁcial effects of bariatric surgery on glucose and weight metabolismwere associated with
changes in the gut microbial communities and were diminished in FXR-deﬁcient mice. Together, these
studies propose that the gut microbiota plays a dominant role in regulating bile acids diversity via FXR
signaling, which in turn affecting obesity and glycemic control. A recent paper published by our group
[84] shows that the bile acid component taurine modiﬁes the microbiome composition, leading to
activation of NLRP6 inﬂammasome signaling and secretion of anti-microbial peptides. Taurine
administration to mice led to amelioration of acute DSS-colitis and the effect depended on the
microbiota and inﬂammasome activation. It will be interesting to check the effect of taurine and other
bile acid components on themicrobiota composition and function in controlling the glycemic response
in homeostasis and in metabolic disorders.
Immune response. Chronic inﬂammation of visceral adipose tissues in obesity has become a
prominent pathological mechanism in which the fat is populated with both adaptive and innate im-
mune cells contributing to systemic insulin resistance and glucose intolerance [70]. Microbiota-derived
pro-inﬂammatory factors may have direct effect on adipose inﬂammation, adiposity, insulin sensitivity
and whole body glycemic control. High levels of gram-negative bacteria-derived lipopolysaccharide
(LPS) that induces endotoxemiawere detected in T2DM patients [85] and in obese and insulin resistant
mice [31]. Administration of LPS to high-fat diet fed mice led to increased serum insulin and adipose
inﬂammation [43], whereas antibiotics treatment of obese and insulin resistant mice signiﬁcantly
changed microbiota composition, abolished adipose tissue inﬂammation, reduced LPS levels and
improved insulin sensitivity [31,86]. Moreover, GF mice introduced with E. Coli strain that produce
immunogenic LPS led to increased macrophage inﬁltration to adipose tissues and augmented adipose
inﬂammation [87]. A recent study by Caesar et al. [32] reported that gut microbial changes derived
from lard diet resulted in induction of Ccl2 and TLR4 signaling in adipose tissues, development of
adipose inﬂammation, with increased serum LPS and adiposity. The metabolic effect was transferrable
to GF mice, whereas gut microbiota from ﬁsh-oil diet given to lard-fed mice counteract the metabolic
phenotype.
Collectively these studies suggest that microbiota-derived or einduced inﬂammatory factors such
as LPS, Ccl2 and TLR4may directly contribute to obesity and its associatedmetabolic disorders, through
induction of adipose tissue inﬂammation, which in turn drives insulin resistance and glucose
intolerance.4. The microbiota as a therapeutic target for improvement of glycemic control
Unlike the human genome, the microbiome may be more readily manipulated and thus may be
considered as a potential therapeutic target. This is an important advantage when considering
microbiome-targeting interventions in a variety of microbiome-associated or edriven pathologies,
such as those related to impaired glycemic control. Microbiota-modulating therapies may aim to
‘correct’ the detrimental microbial composition or function, either by administration of antibiotics or
probiotics, or by transplant of healthy fecal microbiota, which will replace the disease-associated
conﬁguration. Other therapies may attempt to modulate the immune response, by targeting micro-
bial antigens or inﬂammatory signaling cascades impacting the microbiome or impacted by the
microbiome. Examples of these various therapeutic modalities and related open questions will be
further addressed in this section.
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T2DM. However, Membrez et al. demonstrated that modulation of the gut microbiome with nor-
ﬂoxacin and ampicillin improved glycemic control in both diet-induced and genetically-susceptible
hyperglycemic (ob/ob) mice [88]. Similar ﬁndings were reported by Carvalho et al. [86] with high-fat
diet fed mice treated with ampicillin, neomycin and metronidazole, including improvement of
glucose and insulin tolerance, along with reduction in circulating LPS and inﬂammatory cytokines
levels. This suggests that modulation of a dysbiotic gut microbiota may improve insulin signaling and
glucose tolerance by reducing inﬂammation. In a model of viral-induced T1DM, treatment with
trimethoprim/sulfamethoxazole had a protective effects on the rats, possibly by preventing viral-
induced alterations to the gut microbiome [89]. Information regarding the efﬁcacy of antibiotics as a
therapeutic tool in humans is sparse and is somewhat in contrast to the aforementioned ﬁndings [90].
When considering antibiotics as therapeutics for a non-infectious disease, it is important to bear in
mind that they act non-speciﬁcally on the microbiome and eliminate not only the bacteria of interest,
but also other ‘beneﬁcial’ bacteria that are critical for healthy function of the various host systems. In
addition, antibiotics use increases the risk of expansion of pathobionts (commensals that become
pathogenic under speciﬁc conditions) and opportunistic infections [91]. Finally, frequent antibiotics
use contributes to the emergence of antibiotics-resistant pathogens. Taken together, it seems unlikely
in our view that antibiotics will serve as a widely used therapeutic tool for diabetes mellitus. Never-
theless, the aforementioned studies in rodents suggest that amore reﬁned strategy that targets speciﬁc
aberrant members of the microbiota in diabetes may hold a therapeutic potential as microbiome-
targeting treatment in these disorders.
Fecal microbiome transplantation (FMT). FMT has recently gained much attention as an efﬁcient
treatment for recurrent Clostridium difﬁcile infections. In this method, upon transplantation, the fecal
microbiota of a healthy donor is assumed to replace or correct the aberrant composition that underlies
certain pathology in the recipient. In a currently stand-alone, proof-of-concept study, Vrieze et al. [92]
performed small intestine infusions of fecal microbiome to obese individuals. Participants that received
microbiota from lean donors demonstrated improvement of insulin tolerance, as well as compositional
changes in both the small and large intestine microbiota, namely expansion of butyrate-producing
bacteria. No improvement was observed in obese participants that received autologous microbiota.
Although promising, transplantation of a whole microbiome is not risk-free. Even after screening for
pathogens, there is a potential of unwanted effects of the transplanted microbial community on other,
unrelated conditions. Amore targeted approachwould be to transplant selectedmicrobes that improve
insulin tolerance, or administer metabolites produced by the microbiome. In mice, supplementing the
diet with butyrate protects against high fat diet-induced insulin resistance [93]. It remains to be
determined whether such approach has therapeutic potential in humans.
Probiotics and prebiotics. Probiotics can be considered a more speciﬁc approach than trans-
plantation of an entire fecal microbiota community, as they are comprised of a deﬁned combination of
several so-called 'beneﬁcial' bacteria. However, the efﬁcacy of probiotics in promoting health beneﬁts
remains questionable. Several studies determined a beneﬁcial effect for probiotics comprised of Lac-
tobacilli and/or Biﬁdobacteria on both T1DM and T2DM onset and progression in mice [94,95]. In
humans, however, supplementation with probiotics does not always yield similar effects [96], and in a
recent meta-analysis of human trials the authors concluded that probiotics may only modestly affect
glycemic control [97]. An additional interesting bacterium that can be considered as probiotic in the
context of glycemic control is A. muciniphila. Treating high-fat diet fed mice with A. muciniphila
prevents many of the diet-induced metabolic derangements, including glucose intolerance [98,99]. A
novel approach utilizes probiotic bacteria as vectors for local expression of beneﬁcial metabolites. Chen
et al. fed mice with an E. coli strain transformed to express NAPEs (N-acyl-phosphatidylethanolamines,
compounds with known efﬁcacy against obesity in mice). Mice treated with this strain had reduced
levels of obesity and insulin resistance [100].
Prebiotics is a term denoting the use of various foods/nutrients that, upon their supplementation to
the diet, modify the composition of the microbiome to a beneﬁcial one. In the context of diabetes,
feeding high fat diet fed mice with oligofructose increases the abundance of Biﬁdobacteriumwhich is
positively correlated with improved glycemic control [101]. The establishment of both pre- and pro-
biotics as efﬁcient treatments for glucose intolerance still requires further validation in additional
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of action to improve glycemic control.
Personalized dietary interventions. Dietary intake is a signiﬁcant determinant of blood glucose
levels, highlighting the importance of making food choices that induce normal post-prandial glycemic
responses (PPGR) in prevention and treatment of diabetes. Nevertheless, the PPGR to the same food is
different between individuals, rendering global dietary recommendations that are based solely on
intrinsic properties of the food (such as carbohydrates content) inefﬁcient. A recently reported study
denoted a signiﬁcant inter-individual differences to identical foods in a cohort of 800 individuals. By
integrating blood parameters, dietary habits, anthropometrics, physical activity, and gut microbiota
features from this cohort, a machine learning based algorithm was devised that accurately predicted
PPGRs in an independent cohort. A dietary intervention based on predictions by this algorithm resulted
in signiﬁcantly lower postprandial responses [102].
In a dietary intervention study performed by Kovatcheva-Datchary et al., participants supplemented
their diet with barley kernel-based bread for three days. Following this supplementation, microbiota-
dependent improvement in post-prandial glycemic and insulinemic responses were observed, as
response to the beneﬁcial effect of the supplement was dependent on diet-induced bloom of Prevotella
[103]. Considered together, these reports suggest a promising role for microbiome data in designing
personalized diets for prevention and management of hyperglycemia.5. Perspective
Recent technological advances in the ﬁelds of next-generation sequencing and gnotobiology led
to the accumulation of a signiﬁcant body of data regarding the involvement of the microbiome in
common multi-factorial disorders, including those involving an aberrant glycemic response. As the
ﬁeld advances, changes in the microbiomes are no longer considered merely correlative to these
diseases, but in some cases are suggested to play a causative role in disease pathogenesis. In this
review, we highlighted multiple environmental and genetic factors that may alter the microbiome in
a way that impacts the glycemic response. We also describe how the aberrant microbiota may exert
its adverse effects on glycemic response through bacterial metabolite secretion, modulation of
mucosal and systemic immunity or through other, yet unidentiﬁed mechanisms. In this regard, the
microbiome can thus be considered a signaling hub, integrating both endogenous and exogenous
signals to promote net effects on the host glucose homeostasis. There are still many open questions
regarding these interactions. We currently lack a detailed understanding of the nature and mech-
anism of activity of the myriad of factors that affect the microbiome, and are only beginning to
unravel the network of microbiome-host interactions and their contribution to the pathogenesis of
diabetes mellitus.
One critical factor that may impact microbiome research in years to come is its heterogeneity
among individuals, which may provide insights to the individualized responses of people to
environmental stimuli including nutrition, wake-sleep alterations, and medications. Moreover, it is
now appreciated that inter-individual variability in the composition and function of the human
microbiome extends far beyond the healthy state, and particularly in T1DM or T2DM, in which,
despite several commonalities, no unique bacterial signature is identiﬁed across studies. Further-
more, several human trials of various bacteria-targeted therapeutics featured mixed results, which
may possibly be the outcome of inter-individual microbiome variability. It is plausible that clinical
heterogeneity and individualized treatment responsiveness in both T1DM and T2DM may be
inﬂuenced by inter-individual variability in microbiome composition and function. Of equal
importance is heterogeneous microbiome isolation, sequencing and analysis methods by different
groups that at times may affect the obtained results. Thus, one of the critical steps as part of the
‘maturation’ of the microbiome ﬁeld must involve standardization of procedures that would allow
for better reproducibility allowing the integration of microbiome data into clinical practice. Future
research in the ﬁeld may involve personalized microbiome-targeted approaches, utilized for
personalized diagnostics and therapeutics of an altered glycemic response and its complications in
afﬂicted individuals.
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